Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).
Brief Summary: This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.


Options:
A: Arm Label: A1 (any SABA and/or SAMA); Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium, Drug: SABA, Drug: SAMA | Arm Label: A2 (glycopyrronium); Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium, Drug: SABA, Drug: LABA, Drug: SAMA | Arm Label: B1 (any LAMA or LABA and mMRC=1); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: Indacaterol maleate and glycopyrronium bromide, Drug: LAMA, Drug: ICS | Arm Label: B2 (glycopyrronium and mMRC=1); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: Indacaterol maleate and glycopyrronium bromide, Drug: LAMA | Arm Label: C1 (any LABA and ICS); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: ICS | Arm Label: C2 (indacaterol/glycopyrronium); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: ICS | Arm Label: D1 (any LAMA or LABA and mMRC>1); Type: EXPERIMENTAL; Interventions: Drug: LAMA | Arm Label: D2 (indacaterol/glycopyrronium and mMRC>1); Type: EXPERIMENTAL; Interventions: Drug: LAMA | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: SABA; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: LABA; Assigned to Arm(s): A2 (glycopyrronium), B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1), C1 (any LABA and ICS), C2 (indacaterol/glycopyrronium) | Intervention Type: DRUG; Name: Indacaterol maleate and glycopyrronium bromide; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1) | Intervention Type: DRUG; Name: LAMA; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1), D1 (any LAMA or LABA and mMRC>1), D2 (indacaterol/glycopyrronium and mMRC>1) | Intervention Type: DRUG; Name: SAMA; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: ICS; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), C1 (any LABA and ICS), C2 (indacaterol/glycopyrronium)
B: Arm Label: QVA149 110/50 micrograms; Type: EXPERIMENTAL; Interventions: Drug: QVA149 110/50 micrograms | Arm Label: salmeterol/fluticasone 50/500 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/fluticasone 50/500 microgrammes | Intervention Type: DRUG; Name: QVA149 110/50 micrograms; Assigned to Arm(s): QVA149 110/50 micrograms | Intervention Type: DRUG; Name: Salmeterol/fluticasone 50/500 microgrammes; Assigned to Arm(s): salmeterol/fluticasone 50/500 micrograms
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
D: Arm Label: CHF 5993 + Ultibro matched placebo; Type: EXPERIMENTAL; Interventions: Drug: CHF 5993 + Ultibro matched placebo, Procedure: Central spirometry, Other: COPD assessment test, Procedure: Local laboratory Assessments, Other: Saint George's Respiratory Questionnaire, Other: EXACT-pro questionnaire | Arm Label: Ultibro + CHF 5993 matched placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ultibro + CHF 5993 matched placebo, Procedure: Central spirometry, Other: COPD assessment test, Procedure: Local laboratory Assessments, Other: Saint George's Respiratory Questionnaire, Other: EXACT-pro questionnaire | Intervention Type: DRUG; Name: CHF 5993 + Ultibro matched placebo; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo | Intervention Type: DRUG; Name: Ultibro + CHF 5993 matched placebo; Assigned to Arm(s): Ultibro + CHF 5993 matched placebo | Intervention Type: PROCEDURE; Name: Central spirometry; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo | Intervention Type: OTHER; Name: COPD assessment test; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo | Intervention Type: PROCEDURE; Name: Local laboratory Assessments; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo | Intervention Type: OTHER; Name: Saint George's Respiratory Questionnaire; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo | Intervention Type: OTHER; Name: EXACT-pro questionnaire; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo

Answer: C